New and experimental HIV treatments: latest news

New and experimental HIV treatments resources

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

  • New British guidelines recommend treatment for everyone with HIV

    Everyone with HIV who is prepared to take antiretroviral treatment should receive it, regardless of CD4 cell count, new draft British HIV Association (BHIVA) treatment guidelines recommend. The new draft guidelines, published for consultation this week, say that ...

    24 June 2015 | Keith Alcorn
  • Cabotegravir and rilpivirine effective for HIV maintenance therapy at 96 weeks

    An combination of two once-daily oral antiretrovirals – the next-generation integrase inhibitor cabotegravir (GSK1265744) and the approved NNRTI rilpivirine (Edurant, also in Eviplera or Complera) – was as effective as an efavirenz (Sustiva)-based regimen when used as maintenance therapy to keep ...

    19 March 2015 | Liz Highleyman
  • We may need to combine many approaches to achieve a cure, delegates hear

    It is unlikely that one single approach will achieve a cure for HIV infection, delegates at a community cure workshop held the day before the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, heard last ...

    09 March 2015 | Gus Cairns
  • HIV attachment inhibitor BMS-663068 safe and effective in phase 2b study

    Bristol-Myers Squibb's BMS-663068 or fostemsavir, a first-in-class HIV attachment inhibitor that stops the virus from binding to and entering cells, was well-tolerated and demonstrated good antiviral activity in a study presented at the Conference on Retroviruses and Opportunistic Infections ...

    04 March 2015 | Liz Highleyman
  • Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation

    Tenofovir alafenamide (TAF), a new formulation that has lower concentrations in the blood but reaches higher levels in cells, is as effective as the older version, tenofovir disoproxil fumarate (TDF), according to a report at the Conference on Retroviruses and ...

    27 February 2015 | Liz Highleyman
  • HIV maturation inhibitor BMS-955176 looks promising in early study

    A second-generation HIV maturation inhibitor, BMS-955176, demonstrated good safety and high potency, including activity against viral strains that were not susceptible to an earlier drug in this class, researchers reported yesterday at the Conference on Retroviruses and Opportunistic Infections ...

    26 February 2015 | Liz Highleyman
  • Once-daily dolutegravir superior to darunavir/ritonavir in 96-week follow-up

    Treatment with a triple antiretroviral combination containing once-daily integrase inhibitor dolutegravir (Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir (Prezista) over 96 weeks of follow-up, Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported at the HIV Drug ...

    10 November 2014 | Alain Volny-Anne
  • Doravirine works as well as efavirenz with fewer CNS side-effects

    Once-daily doravirine (MK-1439), an experimental NNRTI, demonstrated viral suppression similar to that of efavirenz at 48 weeks, and the dose selected for further development was associated with fewer central nervous system (CNS) side-effects, researchers reported last week at the HIV ...

    10 November 2014 | Liz Highleyman
  • Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine

    Researchers have determined the dose of an injectable formulation of the integrase inhibitor cabotegravir (formerly GSK744) that will be taken into efficacy trials to see if it can be used for pre-exposure prophylaxis (PrEP). Studies in animals were presented earlier ...

    30 October 2014 | Gus Cairns
  • Novel techniques probed in cure research

    Two presentations at the 20th International AIDS Conference (AIDS 2014) in Melbourne described new pathways being explored in the search for either a permanent cure for HIV or for longer-acting drugs. In one, two artificial genes that cause cells ...

    22 July 2014 | Gus Cairns
More news

New and experimental HIV treatments news selected from other sources

  • Could a Subdermal Implant Mean the End of HIV?

    Findings published in Antimicrobial Agents and Chemotherapy report that a novel, subdermal implant delivering potent antiretroviral (ARV) drugs shows extreme promise in stopping the spread of HIV.

    23 hours ago | Edge San Francisco
  • Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide

    Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen that combines Gilead’s emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naïve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen.

    02 July 2015 | Gilead press release
  • European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide (F/TAF) for HIV Treatment

    Gilead Sciences, Inc. today announced that the company’s Marketing Authorization Application (MAA) for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) has been fully validated and is now under evaluation by the European Medicines Agency (EMA). - See more at:

    02 June 2015 | Gilead
  • ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV

    ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for dolutegravir 50mg, for Tentative Approval, to the Food and Drug Administration (FDA), for the treatment of HIV. This is the first ANDA for a generic version of dolutegravir, less than two years after FDA approval of Tivicay® (dolutegravir) for sale in the United States. Upon receiving Tentative Approval from the FDA, Aurobindo Pharma will be able to supply dolutegravir 50mg via the President’s Emergency Plan for AIDS Relief (PEPFAR) programme, following completion of required local regulatory approval process, in the licensed countries outside of the United States, as per the agreement signed between Aurobindo Pharma and ViiV Healthcare in 2014.

    26 May 2015 | ViiV Healthcare
  • EMA Panel Recommends Evotaz for Adults With HIV-1

    The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended granting marketing authorization for atazanavir/cobicistat (Evotaz, Bristol-Myers Squibb Pharma EEIG) for the treatment of adults with HIV-1 infection and no known mutations associated with atazanavir resistance

    26 May 2015 | Medscape
  • New subdermal implant delivers potent antiretroviral drugs

    A novel, subdermal implant delivering potent antiretroviral drugs shows extreme promise in stopping the spread of HIV, researchers report. Scientists say that they have developed a matchstick size implant, similar to a contraceptive implant, that successfully delivers a controlled, sustained release of tenofovir alafenamide up to 40 days in dogs with no adverse side effects.

    29 April 2015 | Science Daily
  • Six questions about HIV/AIDS that deserve more attention

    As HIV investigators work to control and eradicate the virus worldwide, certain myths or misconceptions about the disease have been embraced, whereas other concepts with merit have been left relatively unexplored, argues American HIV/AIDS researcher Jay Levy, M.D., in a Trends in Molecular Medicine commentary. He calls on fellow researchers to continue questioning and not to lose sight of alternative strategies that could ultimately lead to a sustainable, long-term solution to HIV infection.

    15 April 2015 | Eurekalert Inf Dis
  • Mechanism of action of ABIVAX’s First-in-class anti-HIV drug published today in peer-reviewed journal Retrovirology

    ABX464 blocks viral replication by preventing the export of viral RNA from the nucleus to the cytoplasm in infected cells. This transport is normally mediated by a viral protein called Rev, and the activity of Rev is efficiently inhibited by ABX464. Never targeted before, Rev has been postulated of potential interest for HIV treatment for some time, but ABX464 is the first molecule under development aimed at inhibiting it.

    14 April 2015 | ABIVAX press release
  • Editing HIV out of our genome with CRISPR

    In an attempt to render latent HIV completely harmless, UMass Medical School researchers are using CRISPR/Cas9, a powerful gene editing tool, to develop a novel technology that can potentially cut the DNA of the latent virus out of an infected cell.

    13 April 2015 | University of Massacusetts Medical Schoool press release
  • Broadly Neutralizing Antibody Suppresses HIV in Clinical Trial

    There is now intense interest in learning whether the blossoming array of broadly neutralizing antibodies (bNAbs) can be put to therapeutic and preventive use. A paper published yesterday in Nature describes encouraging results from a phase I trial involving the bNAb 3BNC117. Reflecting the level of interest in the topic, the paper has attracted extensive press coverage.

    10 April 2015 | TAG
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.